Recently Featured

Astellas to Close Stem Cell Therapy Site; GSK Advances ADC Trials; Daiichi Sells OTC Unit for $1.55 Billion

April 18, 2026
Astellas Pharma has announced the closure of its stem cell therapy site, a strategic pivot that reflects ongoing challenges in the field of regenerative medicine. This decision underscores the complexities associated with stem cell therapies, particularly in achieving regulatory approval and market viability. As Astellas reallocates resources, the industry may witness a shift in focus…

BIO Launches ‘Fight of Our Lives’ Campaign to Celebrate 50 Years of Biotech Innovation

April 17, 2026
The Biotechnology Innovation Organization (BIO) has initiated a nationwide campaign titled “The Fight of Our Lives” to commemorate the 50th anniversary of the biotech industry. This campaign includes a compelling video and a suite of materials designed to highlight the transformative stories behind biotech breakthroughs and their profound impact on patient lives. This initiative not…

Vaccine Skepticism Misrepresented in Recent Polling Data

April 17, 2026
Recent polling data from Politico suggests that more Americans doubt vaccine safety than trust it, a claim that has raised significant concerns among public health experts. This narrative, if accepted at face value, could have profound implications for vaccination rates and public health initiatives. The framing of such skepticism as widespread may inadvertently normalize hesitancy,…

Ongoing Cases